SALIOGEN THERAPEUTICS
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
SALIOGEN THERAPEUTICS
Industry:
Biotechnology Genetics Life Science Therapeutics
Founded:
2020-01-01
Address:
Burlington, Massachusetts, United States
Country:
United States
Website Url:
http://www.saliogen.com
Total Employee:
11+
Status:
Active
Contact:
(650) 906-9468
Total Funding:
135 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Parthenon Therapeutics
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Ray Therapeutics
Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
SymBiosis LLC
SymBiosis LLC investment in Series B - SalioGen Therapeutics
D1 Capital Partners
D1 Capital Partners investment in Series B - SalioGen Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - SalioGen Therapeutics
Retinal Degeneration Fund
Retinal Degeneration Fund investment in Series B - SalioGen Therapeutics
GordonMD Global Investments
GordonMD Global Investments investment in Series B - SalioGen Therapeutics
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Series B - SalioGen Therapeutics
T. Rowe Price
T. Rowe Price investment in Series B - SalioGen Therapeutics
EPIQ Capital Group
EPIQ Capital Group investment in Series B - SalioGen Therapeutics
PBM Capital Group
PBM Capital Group investment in Series A - SalioGen Therapeutics
Official Site Inspections
http://www.saliogen.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SalioGen Therapeutics"
About Us - SalioGen Therapeutics
Before SalioGen, Sandeep worked for 24 years at Pfizer. Recently, his team successfully brought Pfizer’s COVID-19 LNP-mRNA vaccine to the clinic and achieved emergency use authorization. In his last role as Executive Director, …See details»
SalioGen Therapeutics - Crunchbase Company Profile …
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a …See details»
Science - Gene Coding™ Technology | SalioGen …
Before SalioGen, Sandeep worked for 24 years at Pfizer. Recently, his team successfully brought Pfizer’s COVID-19 LNP-mRNA vaccine to the clinic and achieved emergency use authorization. In his last role as Executive Director, …See details»
SalioGen Therapeutics - The Org
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative …See details»
SalioGen Therapeutics - LinkedIn
SalioGen Therapeutics | 3,257 followers on LinkedIn. Accelerating the impact of genetic medicines for patients with Gene Codingâ„¢ technology | SalioGen Therapeutics is a …See details»
SalioGen Therapeutics Company Profile 2024: Valuation, Funding ...
SalioGen Therapeutics is headquartered in Lexington, MA. What is the size of SalioGen Therapeutics? SalioGen Therapeutics has 75 total employees. What industry is SalioGen …See details»
SalioGen Therapeutics - Contacts, Employees, Board Members
Organization. SalioGen Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Number of Board Member and Advisor …See details»
SalioGen Therapeutics Overview | SignalHire Company Profile
SalioGen Therapeutics is a biotechnology company on a mission to accelerate the impact of genetic medicine for patients using its novel Gene Codingâ„¢ technology. Gene Coding is a non …See details»
Saliogen Therapeutics, Inc. Company Profile | Lexington, MA ...
Find company research, competitor information, contact details & financial data for Saliogen Therapeutics, Inc. of Lexington, MA. Get the latest business insights from Dun & Bradstreet.See details»
SalioGen Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore SalioGen Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 news, and 1 literature, Disease Domain:Endocrinology and Metabolic Disease, Nervous …See details»
SalioGen Therapeutics - Craft
SalioGen Therapeutics is a company developing genetic medicine for patients with inherited disorders. It uses a genetic modification approach that works by adding a new genomic code …See details»
SalioGen Therapeutics Announces Closing of $20 Million Series A ...
Mar 1, 2021 Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy Financing to fund SalioGen’s pipeline in genetic diseases, based on …See details»
Cystic Fibrosis Foundation Announces Investment in SalioGen ...
Jan 5, 2022 SalioGen’s Gene Coding TM approach is designed to turn on, turn off, or modify the function of any gene in the genome. ... The Foundation funds more CF research than any …See details»
SalioGen Therapeutics Closes $115 Million Oversubscribed Series B ...
Jan 5, 2022 SalioGen is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on …See details»
SalioGen Therapeutics Strengthens its Leadership Team to …
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic …See details»
SalioGen Therapeutics Announces Closing of $20 Million Series A ...
Mar 1, 2021 SalioGen’s initial focus is on in vivo non-viral gene therapy, but EDIT also has the potential to streamline cell therapy, cell engineering, and biologics manufacturing to help an …See details»
Careers - SalioGen Therapeutics
Before SalioGen, Sandeep worked for 24 years at Pfizer. Recently, his team successfully brought Pfizer’s COVID-19 LNP-mRNA vaccine to the clinic and achieved emergency use …See details»
SalioGen Therapeutics hit by layoffs, as gene-editing biotechs
Oct 13, 2024 SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions.See details»
New Possibilities for Patients | SalioGen Therapeutics
Before SalioGen, Sandeep worked for 24 years at Pfizer. Recently, his team successfully brought Pfizer’s COVID-19 LNP-mRNA vaccine to the clinic and achieved emergency use …See details»